Photo: Max Gelman for Endpoints News

Bis­pecifics con­tin­ue im­pres­sive ef­fi­ca­cy streak, but com­pa­nies look to re­duce side ef­fects: #ASH23

SAN DIEGO — Bis­pe­cif­ic an­ti­bod­ies from Re­gen­eron, John­son & John­son, Ab­b­Vie and Roche con­tin­ue to show im­pres­sive ef­fi­ca­cy in lym­phomas and myelo­ma based on new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.